Sea buckthorn bud extract displays activity against cell-cultured Influenza virus

A. TORELLI1, E. GIANCHECCHI1, S. PICCIRELLA1, A. MANENTI1, G. PICCINI1, E. LLORENTE PASTOR1, B. CANOV1, E. MONTOMOLI1,2,3

1 VisMederi Srl, Siena, Italy; 2 Pool Pharma - MI - Scientific Director, San Giuliano Milanese, Italy; 3 University of Siena, Italy

Key words
Sea buckthorn plant extract • Influenza prevention • Antivirals

Introduction. Vaccines and antiviral drugs are the most widely used methods of preventing or treating Influenza virus infection. The role of sea buckthorn (SBT) bud dry extract as a natural antiviral drug against Influenza was investigated.

Methods. Influenza virus was cultured in the MDCK cell line, with or without SBT bud extract, and virus growth was assessed by HA and TCID50 virus titration in terms of cytopathic effect on cells. Several concentrations of extract were tested, the virus titer being measured on day 4 after infection.

Results. After infection, the virus titer in the control sample was calculated to be 2.5 TCID50/ml; treatment with SBT bud extract reduced the virus titer to 2.0 TCID50/ml at 50 µg/ml, while the HA titer was reduced from 1431 (control) to 178. Concentrations lower than 50µg/ml displayed an inhibitory effect in the HA assay, but not in the TCID50 virus titration; however, observation of the viral cultures confirmed a slowdown of viral growth at all concentrations.

Discussion. Natural dietary supplements and phytotherapy are a growing market and offer new opportunities for the treatment of several diseases and disorders. These preliminary experiments are the first to show that SBT bud extract is able to reduce the growth of the Influenza A H1N1 virus in vitro at a concentration of 50 µg/ml. This discovery opens up the possibility of using SBT bud extract as a valid weapon against Influenza and, in addition, as the starting-point for the discovery of new drugs.
All parts of SBT contain large amounts of several active compounds [16] and these include: vitamins (folic acid, vitamin C, vitamin A, vitamin E, vitamin K, riboflavin), carotenoids (lycopene α, β, δ-carotene), phytosterols (amyrins, ergosterol, stigmasterol, lanosterol), organic acids (malic and oxalic acids), polyunsaturated fatty acids and essential amino acids [17].

Several medicinal and therapeutic applications utilize the extracts obtained from the leaves of this plant, which display immunomodulatory [18] and anti-inflammatory [19] properties, as demonstrated by Padwad and colleagues [16]. Furthermore, SBT leaves also exert antiviral, anti-bacterial and anti-tumor effects [20, 21]. Preliminary results have also shown that SBT seed extracts have anti-bacterial activity (for example against Listeria monocytogenes and Yersinia enterocolitica) [22, 23] and anti-viral activities, as reported by the group of Jain against Dengue virus [24].

SBT bud extracts are present in commercial dietary supplements, such as preparations of nutrient and vitamin products [25, 26], and are formulated into Influpirin viroprotection products [25, 26], and are formulated into Influpirinviroprotection against Dengue virus [24].

The aim of the present study was to evaluate the therapeutic anti-viral potential of SBT bud extracts on Influenza A/H1N1 virus infection in Madin Darby Canine Kidney cells (MDCK). In 2009, this viral strain was responsible for an Influenza pandemic that spread rapidly around the world [27]. Moreover, it currently circulates in the population, causing seasonal outbreaks, and its antigens are included in the available seasonal influenza vaccines [28].

Methods

Cells and Cell Cultures

Madin Darby Canine Kidney (MDCK) cells were purchased from Sigma-Aldrich (ECACC, Public Health England, Porton Down, United Kingdom) and cultured in Minimum Essential Medium Eagle (EMEM medium) supplemented with 2mM Glutamine, 10% Fetal Bovine Serum (FBS) EU Approved (Euroclone, Pero, Italy) and 100UI/ml of penicillin-streptomycin. MDCK cells were seeded at a density of 6.5 x 10^5 cells/ml in 6-well plates in complete EMEM medium and were incubated for 24 h at 37°C in 5% CO2 and subcultures were performed every 3-4 days [29]. Except where indicated otherwise, all the above reagents were from Lonza (Verviers, Belgium).

SBT Bud Dry Extract

SBT bud dry extract from PoolPharma S.r.l. (San Giuliano Milanese, Italy) was weighed on a precision scale and dissolved in sterile Dulbecco’s Phosphate-Buffered Saline (DPBS) at a final concentration of 1 mg/ml; the pH of the solution was measured (6.96). The dissolved extract was then sterile-filtered through a 0.22 µm filter.

Influenza A/California/7/2009 (H1N1) Virus

Influenza A/California/7/2009 (H1N1) virus was obtained from the National Institute for Biological Standards and Control (NIBSC) (Potters Bar, Hertfordshire, United Kingdom) and used according to the instructions provided by the supplier. The virus was propagated in MDCK cells [30], harvested and stored at -80°C. The propagated virus had a tissue culture infectious dose (TCID50) titer of 10^{13}.

Viral Growth

Influenza A/California/7/2009 (H1N1) virus was propagated in MDCK cells cultured in UltraMDCK serum-free-medium (SFM) supplemented with 0.5 µg/ml of trypsin from bovine pancreas (TPCK) (Sigma-Aldrich, Saint Louis, MO, USA) and 100 UI/ml of penicillin-streptomycin. MDCK cells were seeded in a T25 cm² tissue culture flask at a density of 1 x 10^6 cells/ml. After 24 hours (h), the cell medium was discarded and the cells were washed twice with sterile DPBS. After the DPBS had been discarded from the flask, the cells were treated with 500 µl of virus inoculum (5 ml of solution containing 50 µl of virus at 10^{3.5} TCID50/ml (1:100 dilution) and 2.5 µl of TPCK, and incubated for 1 h at 37°C in 5% CO2. After 1 h, the inoculum was removed, the cells were washed with DPBS, and fresh UltraMDCK SFM, supplemented as previously described, was added. The cells were incubated at 37°C in 5% CO2, and the cytopathic effect was monitored every day until post-infection day 4. The culture medium was collected and analyzed for TCID50 and hemagglutination titer on the 4th day after infection.

Effect of SBT Bud Dry Extract on MDCK Cells

MDCK cells were seeded at a density of 6.5 x 10^5 cells/ml in 6-well plates in complete EMEM medium and were incubated for 24 h at 37°C in 5% CO2. SBT at different concentrations (1 µg/ml, 5 µg/ml, 10 µg/ml, 30 µg/ml, 50 µg/ml, 75 µg/ml and 100 µg/ml) was then added to the medium in the wells. The cells were checked at 24 h, 48 h and 72 h by means of a light optical microscope to evaluate whether the extract had a cytotoxic effect on them. The experiment was repeated to confirm the preliminary results.

Effect of SBT on Viral Growth

The viral growth procedure was repeated in the conditions reported above. After infection, the inoculum was removed and the medium was replaced with fresh Ultra-MDCK SFM (supplemented with 100 UI/ml of penicillin-streptomycin and 0.5 g/ml of TPCK) containing different concentrations of SBT: 2.5 µg/ml, 5 µg/ml, 7.5 µg/ml, 10 µg/ml, 30 µg/ml, 50 µg/ml, 75 µg/ml and 100 µg/ml. The infection grade was observed daily for cytopathic effect, and the culture medium was harvested on day 4 to be analyzed for virus content in terms of TCID50 and hemagglutination titer. In parallel, two control flasks were run: the first flask represented the cell control and...
Sea buckthorn bud extract displays activity against cell-cultured influenza virus.

**Virus titration by hemagglutination test**

The ability of the influenza virus to agglutinate red blood cells from certain mammalian or avian species can be exploited to check for the presence and hemagglutinating activity of the virus in biological substrates (e.g., serum samples) [31, 32]. To evaluate the hemagglutinating capability of the virus in previously infected cell cultures, the hemagglutination test was used: 100 µl of culture medium from the flask of interest was transferred to the 1st well of a 96-well V bottom plate then 50 µl of saline solution (0.9% NaCl) (Sigma-Aldrich, Saint Louis, MO, USA) was added from well 2 up to well 12; 2-fold serial dilutions of the culture medium (contained in the 1st well) in the saline solution (wells 2-12) were performed from the 1st well up to the 12th well.

Then, 50 µl of turkey red blood cell (RBC) suspension (0.5% in saline solution) (Emozoo Snc, Casole d’Elsa, Italy) was added to each well and the plate was incubated for 45 minutes at room temperature (RT). After incubation, the plate was tilted to allow non-hemagglutinated RBCs to drip from the bottom of the wells and the result was read; the reciprocal of the highest dilution of the culture medium that was still able to cause agglutination indicated the titer of the virus in the culture medium. The experiment was repeated, this time with a 1:10 starting dilution of the culture media, and the virus titer was calculated in terms of hemagglutinating units (HAU) in 1 ml by applying the following formula: HAU in 1 ml = 20 x 10 \((\frac{\Sigma X_1}{n})\) where 

\[ \text{HAU in 1 ml} = 20 \times 10^{\frac{\Sigma X_1}{n}} \]

**Virus titration by TCID50**

The “TCID50” titer is the viral dose that gives rise to a cytopathic effect in 50% of cells in the inoculated culture. The virus titer was determined by means of the TCID50 assay, using the Spearman/Karber method [33] on treated MDCK cells, as reported by Lugovtsev [34]. Twelve plastic tubes (1.5 ml) were prepared and loaded with 900 µl of cell medium (EMEM), except for the 11th tube; 100 µl of supernatants from cultures was then transferred into the first tube and serial 10-fold dilutions were performed from tube 1 to up to tube 10. The contents of the tubes were transferred into a 96-well cell culture plate; the content of the 1st tube was transferred into the 1st column of the plate, the content of the 2nd tube was transferred into the 2nd column, and so on up to the 10th tube. The 11th tube was left empty. At the end of the dilution steps, 100 µl of cell suspension (in complete EMEM medium, with 0.5% FBS and 0.5 µg/ml of TPCK, at a cell density of 5 x 10^5 cells/ml) was added to each well. The 12th column, containing only cell medium and cell suspension, was used as a cell control. The plates were incubated for 5 days and the TCID50 titer was evaluated by checking the cytopathic effect in the cell mono-layer by means of a light microscope. The results were calculated by applying the Spearman/Karber formula [33]:

\[ \text{TCID50/100\mu l} = X_0 - \frac{1}{2} + \frac{d}{2 + \left(\Sigma X_i/n\right)} \]

where \(X_0\) is the positive logarithm of the highest dilution at which all wells are positive for cytopathic effect, \(d\) represents the dose distance in log, \(n\) is the number of repeats per dilution and \(\Sigma X_i\) is the sum of all positive wells, starting from \(X_0\). In the case of 10-fold dilution, \(d=\log_{10}10=1\) and the formula can be simplified to

\[ \text{TCID50/100\mu l} = X_0 - \frac{1}{2} + \left(\Sigma X_i/n\right) \]

**Results**

**Evaluation of the cytotoxic effect of SBT on MDCK cells**

The possible cytotoxic effect of SBT on MDCK cells previously infected with Influenza A H1N1 virus was evaluated by means of direct observation of cells under a light optical microscope. SBT treatment of MDCK cells showed no cytotoxic effect up to a concentration of 50 µg/ml. At 75 µg/ml and 100 µg/ml SBT had a cytotoxic effect on the cells: at 75 µg/ml, the cell monolayer had a discontinuous appearance and floating cells were present in the culture medium; this effect was more evident at a concentration of 100 µg/ml (Tab. I).

**Tab. I.** Evaluation of the cytotoxic effect of SBT on MDCK cells. This table shows the effect of different concentrations of SBT on MDCK cell cultures after 72 h of incubation. The concentrations of SBT tested were: 1 µg/ml, 5 µg/ml, 10 µg/ml, 50 µg/ml, 50 µg/ml, 75 µg/ml and 100 µg/ml. No toxic effect was observed up to a concentration of 75 µg/ml. At 75 µg/ml and 100 µg/ml of SBT, the cells in the wells showed signs of toxicity: discontinuous cell layer and floating cells in the medium.

<table>
<thead>
<tr>
<th>SBT concentration (µg/ml)</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell control</td>
<td>No effect</td>
</tr>
<tr>
<td>1 µg/ml</td>
<td>No effect</td>
</tr>
<tr>
<td>5 µg/ml</td>
<td>No effect</td>
</tr>
<tr>
<td>10 µg/ml</td>
<td>No effect</td>
</tr>
<tr>
<td>50 µg/ml</td>
<td>No effect</td>
</tr>
<tr>
<td>75 µg/ml</td>
<td>Discontinuous cell layer, floating cells</td>
</tr>
<tr>
<td>100 µg/ml</td>
<td>Discontinuous cell layer, floating cells</td>
</tr>
</tbody>
</table>

**SBT effect on viral growth results**

**Hemagglutination titer results**

The ability of SBT bud extract to reduce Influenza H1N1 viral growth was evaluated on post-infection day 4. MDCK cell culture supernatants were harvested from the culture plates and assayed for hemagglutination titer. Concentrations of SBT ranging from 2.5 µg/ml to 50 µg/ml markedly reduced the hemagglutination titer from 28621.6 HAU/ml (the value obtained from the viral growth control sample) (Fig. 1). The two highest concentrations of SBT used (75 µg/ml and 100 µg/ml) completely inhibited viral growth. However, they dis-
played a toxic effect on the cells; the results obtained at these high concentrations may therefore be affected cell toxicity, as was observed after staining the cell cultures with Trypan blue.

**TCID50 virus titration results**

Cell culture supernatants were harvested on day 4 after infection and treatment and assayed for TCID50 virus titer to assess the number of infectious (live) viral particles released from the infected cells in the culture medium. The cytopathic effect was evaluated on day 5. The treatment of viral cultures with SBT at a concentration of 50 µg/ml markedly reduced the viral titer in terms of TCID50 (Fig. 2). At 75 µg/ml and 100 µg/ml, SBT totally inhibited viral growth, but in these cases the results could be affected by SBT toxicity. These results represent a mean of two experiments (n = 2).

**Discussion**

In recent years, since the spread of resistant viral strain towards the available pharmacologic treatments and the occurrence of unpredictable pandemics, many investigations have been carried out on new computer-designed molecules or available compounds in a search for new...
anti-influenza drugs. In the present study, the antiviral activity of SBT bud extract (contained in Influpirinval®) against influenza H1N1 A/California/7/2009 was evaluated in vitro on MDCK cells infected with this virus. A previous study conducted by Jain and colleagues [24] demonstrated that SBT leaf extract at a concentration of 50 μg/ml exerted an antiviral activity against Dengue virus. We found that SBT bud extract had an antiviral activity on influenza virus H1N1, especially at 50 μg/ml (the same concentration used by Jain’s group). Specifically, after 4 days the viral titer was evaluated in terms of TCID50 titer and hemagglutination titer upon treatment with SBT bud extract; both methods revealed that, at 50 μg/ml, the viral titer was reduced in comparison with the virus control. Direct observation of the virus cultures confirmed the antiviral activity at 50 μg/ml, although an antiviral effect was also visible at lower concentrations, starting from 2.5 μg/ml. When SBT was used at high concentrations (75 μg/ml and 100 μg/ml), viral growth was completely inhibited. However, the treatment had an adverse effect on cell cultures, and this could have affected the results obtained at these concentrations.

Conclusions

The data obtained from this preliminary study confirmed that SBT bud extract has an antiviral activity on influenza H1N1 A/California/7/2009 in vitro, supporting its potential use as an anti-influenza agent. Nevertheless, further investigations are needed in order to generate more data, to evaluate the preventive role of SBT treatment against Influenza infection, and to understand the specific mechanism of action of this extract both in vitro and in vivo.

References


[34] Lugovtsev VY, Melnyk D, Weir JP. Heterogeneity of MDCK cell line and its applicability for Influenza virus research. PLoS ONE 2013;8:e75014.

Received on April 28, 2015. Accepted on May 26, 2015.

Conflicts of interests: Dr. Brenno Canovi is the Scientific Director of Pool Pharma, the company that distributes the Influpirinviral®, the dietary supplement containing sea buckthorn bud extract.

Correspondence: Alessandro Torelli, VisMederi Srl, via Fiorentina 1, 53100 Siena, Italy - Tel. +39 0577 231254 - Fax +39 0577 43444 - E-mail: torelli@vismederi.com